BRPI0811262A2 - Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo - Google Patents

Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo

Info

Publication number: BRPI0811262A2
Authority: BR; Brazil
Prior art keywords: compound; diseases; salt; homeostase; glycorticoid
Prior art date: 2007-05-29

Application number

BRPI0811262-2A2A

Other languages

English (en)

Inventor

Mamoru Matsuda

Toshiyuki Mori

Masato Nagatsuka

Sachiko Kobayashi

Masatomo Kato

Miwa Takai

Original Assignee

Santen Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-29

Filing date

2008-05-29

Publication date

2014-11-04

2008-05-29 Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd

2014-11-04 Publication of BRPI0811262A2 publication Critical patent/BRPI0811262A2/pt

Links

150000001875 compounds Chemical class 0.000 title 3
150000003839 salts Chemical class 0.000 title 2
208000010412 Glaucoma Diseases 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
208000027866 inflammatory disease Diseases 0.000 title 1
208000030159 metabolic disease Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000002265 prevention Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Neurology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Transplantation (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0811262-2A2A 2007-05-29 2008-05-29 Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo BRPI0811262A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2007141568		2007-05-29
PCT/JP2008/059866 WO2008146871A1 (ja)	2007-05-29	2008-05-29	グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体

Publications (1)

Publication Number	Publication Date
BRPI0811262A2 true BRPI0811262A2 (pt)	2014-11-04

Family

ID=40075104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0811262-2A2A BRPI0811262A2 (pt)	2007-05-29	2008-05-29	Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo

Country Status (14)

Country	Link
US (2)	US8193187B2 (pt)
EP (1)	EP2151436B1 (pt)
JP (1)	JP5183302B2 (pt)
KR (1)	KR20100022456A (pt)
CN (1)	CN101679317B (pt)
AU (1)	AU2008255733B8 (pt)
BR (1)	BRPI0811262A2 (pt)
CA (1)	CA2687948A1 (pt)
ES (1)	ES2419239T3 (pt)
MX (1)	MX2009012885A (pt)
NZ (1)	NZ581666A (pt)
PL (1)	PL2151436T3 (pt)
RU (1)	RU2498980C2 (pt)
WO (1)	WO2008146871A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1995242T3 (pl)	2006-03-14	2013-03-29	Santen Pharmaceutical Co Ltd	Nowa pochodna 1,2,3,4-tetrahydrochinoksaliny, mająca aktywność wiążącą receptor glukokortykoidowy
WO2008146871A1 (ja) *	2007-05-29	2008-12-04	Santen Pharmaceutical Co., Ltd.	グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
US20090042936A1 (en) *	2007-08-10	2009-02-12	Ward Keith W	Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
KR20110053467A (ko) *	2008-09-12	2011-05-23	산텐 세이야꾸 가부시키가이샤	술폰산에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2,3,4-테트라히드로퀴녹살린 유도체를 포함하는 글루코코르티코이드 수용체 작용제
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
SG191710A1 (en)	2011-01-21	2013-08-30	Eisai R&D Man Co Ltd	Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
US20120316199A1 (en)	2011-06-07	2012-12-13	Ward Keith W	Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201336526A (zh)	2012-01-31	2013-09-16	參天製藥股份有限公司	非水性液體組成物
TW201609145A (zh)	2013-12-25	2016-03-16	參天製藥股份有限公司	注射劑及形成緩釋（ｄｅｐｏｔ）之方法
JP2017043614A (ja) *	2015-08-25	2017-03-02	参天製薬株式会社	［４−（１，３，３−トリメチル−２−オキソ−３，４−ジヒドロ−１ｈ−キノキサリン−７−イル）フェノキシ］エチルオキシ化合物またはその塩
US11433090B2 (en)	2017-06-16	2022-09-06	The Doshisha	mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
EP3639855A4 (en)	2017-06-16	2021-03-17	The Doshisha	COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT
US10981918B2 (en) *	2018-07-20	2021-04-20	Grünenthal GmbH	Further substituted triazolo quinoxaline derivatives
WO2020016453A1 (en) *	2018-07-20	2020-01-23	Grünenthal GmbH	Substituted triazolo quinoxaline derivatives
WO2025111184A1 (en)	2023-11-21	2025-05-30	Fmc Corporation	Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6369057B1 (en) *	1991-04-15	2002-04-09	Aventis Pharma Deutschland Gmbh	Quinoxalines, processes for their preparation and their use
EP0509398B1 (de)	1991-04-15	2001-09-19	Aventis Pharma Deutschland GmbH	Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung
HU223945B1 (hu) *	1994-09-27	2005-03-29	Yamanouchi Pharmaceutical Co., Ltd.	1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények
WO1997020578A1 (en)	1995-12-04	1997-06-12	University Of Miami	Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6340758B1 (en)	1997-05-16	2002-01-22	Warner-Lambert Company	Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
DE60113032T2 (de)	2000-10-30	2006-07-06	Pfizer Products Inc., Groton	Glukokortikoidrezeptor-Modulatoren
US7329680B2 (en)	2003-04-30	2008-02-12	The Institute For Pharmaceutical Discovery, Llc	Heterocycle substituted carboxylic acids
US7235662B2 (en) *	2003-06-11	2007-06-26	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor and method
US20070249011A1 (en)	2004-03-04	2007-10-25	Riken	Method for Screening Fungus-Specific Antimicrobial Agent and Kit Therefor
KR20070046150A (ko)	2004-07-28	2007-05-02	아이알엠 엘엘씨	스테로이드 호르몬 핵 수용체의 조절제로서의 화합물 및조성물
EP1944290B1 (en) *	2005-09-14	2013-12-04	Santen Pharmaceutical Co., Ltd.	Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity
PL1995242T3 (pl) *	2006-03-14	2013-03-29	Santen Pharmaceutical Co Ltd	Nowa pochodna 1,2,3,4-tetrahydrochinoksaliny, mająca aktywność wiążącą receptor glukokortykoidowy
JP5054996B2 (ja) *	2006-03-14	2012-10-24	参天製薬株式会社	グルココルチコイド受容体結合活性を有する新規１，２，３，４−テトラヒドロキノキサリン誘導体
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
PL2085388T3 (pl) *	2006-11-14	2013-01-31	Santen Pharmaceutical Co Ltd	Nowa pochodna 1,2-dihydrochinoliny, zawierająca jako podstawniki podstawioną grupę fenyloamino-niższą alkilową oraz wprowadzoną przez ester grupę fenylową
WO2008111632A1 (ja)	2007-03-13	2008-09-18	Santen Pharmaceutical Co., Ltd.	２，２，４－トリメチル－６－フェニル－１，２－ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
WO2008146871A1 (ja) *	2007-05-29	2008-12-04	Santen Pharmaceutical Co., Ltd.	グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体
WO2009035067A1 (ja)	2007-09-13	2009-03-19	Santen Pharmaceutical Co., Ltd.	１，３，３－トリメチル－７－フェニル－３，４－ジヒドロ－１ｈ－キノキサリン－２－オン誘導体からなるグルココルチコイド受容体アゴニスト
JP2009084274A (ja)	2007-09-13	2009-04-23	Santen Pharmaceut Co Ltd	新規１，３，３−トリメチル−７−フェニル−３，４−ジヒドロ−１ｈ−キノキサリン−２−オン誘導体

2008
- 2008-05-29 WO PCT/JP2008/059866 patent/WO2008146871A1/ja not_active Ceased
- 2008-05-29 NZ NZ581666A patent/NZ581666A/en not_active IP Right Cessation
- 2008-05-29 EP EP08764835.8A patent/EP2151436B1/en not_active Not-in-force
- 2008-05-29 AU AU2008255733A patent/AU2008255733B8/en not_active Ceased
- 2008-05-29 RU RU2009149185/04A patent/RU2498980C2/ru not_active IP Right Cessation
- 2008-05-29 KR KR1020097024711A patent/KR20100022456A/ko not_active Ceased
- 2008-05-29 MX MX2009012885A patent/MX2009012885A/es active IP Right Grant
- 2008-05-29 JP JP2008140300A patent/JP5183302B2/ja not_active Expired - Fee Related
- 2008-05-29 US US12/451,653 patent/US8193187B2/en not_active Expired - Fee Related
- 2008-05-29 PL PL08764835T patent/PL2151436T3/pl unknown
- 2008-05-29 CA CA002687948A patent/CA2687948A1/en not_active Abandoned
- 2008-05-29 CN CN2008800179279A patent/CN101679317B/zh not_active Expired - Fee Related
- 2008-05-29 ES ES08764835T patent/ES2419239T3/es active Active
- 2008-05-29 BR BRPI0811262-2A2A patent/BRPI0811262A2/pt not_active IP Right Cessation
2012
- 2012-02-02 US US13/364,680 patent/US8569493B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN101679317A (zh)	2010-03-24
KR20100022456A (ko)	2010-03-02
AU2008255733B2 (en)	2013-06-06
US20100137307A1 (en)	2010-06-03
US8193187B2 (en)	2012-06-05
PL2151436T3 (pl)	2013-09-30
EP2151436A4 (en)	2011-08-03
MX2009012885A (es)	2009-12-10
WO2008146871A1 (ja)	2008-12-04
CN101679317B (zh)	2012-10-31
EP2151436A1 (en)	2010-02-10
ES2419239T3 (es)	2013-08-20
RU2009149185A (ru)	2011-07-10
CA2687948A1 (en)	2008-12-04
US8569493B2 (en)	2013-10-29
AU2008255733A8 (en)	2013-06-13
NZ581666A (en)	2011-06-30
AU2008255733B8 (en)	2013-06-13
AU2008255733A1 (en)	2008-12-04
JP5183302B2 (ja)	2013-04-17
US20120129866A1 (en)	2012-05-24
EP2151436B1 (en)	2013-04-24
RU2498980C2 (ru)	2013-11-20
JP2009007344A (ja)	2009-01-15

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-03-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2022-07-12	B350	Update of information on the portal [chapter 15.35 patent gazette]

Publication	Publication Date	Title
BRPI0811262A2 (pt)	2014-11-04	Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo
BRPI0917138A2 (pt)	2015-11-17	composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BRPI0820868A2 (pt)	2019-09-24	composto de tiofeno fórmula(i), composição farmacêutica contendo o mesmo e uso deste para a prevenção ou tratamento de doenças ou disturbíos associados a um sistema imune ativado
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0821110B8 (pt)	2021-05-25	anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BRPI0806531A2 (pt)	2014-04-22	Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI1009252A2 (pt)	2016-03-15	composto, pró-droga, composição farmacêutica, métodos para prevenir ou tratar doenças do sistema nervoso central, e mal de alzheimer, e, uso do composto ou de uma pró-droga do mesmo
BRPI0812740A2 (pt)	2016-07-19	composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
CL2007003472A1 (es)	2008-08-22	Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
BRPI0615150A2 (pt)	2017-06-20	agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
BRPI1013763A2 (pt)	2015-08-25	Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
CL2007002974A1 (es)	2008-05-23	Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
CL2007003192A1 (es)	2008-06-20	Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario.
BRPI0814529A2 (pt)	2015-01-27	Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
ECSP12012326A (es)	2013-01-31	Derivados de aminopirimidina como moduladores de la lrrk2
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI1009860A2 (pt)	2016-03-08	composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BRPI0822026A2 (pt)	2014-10-07	Prepação farmacêutica ou nutracêutica revestida com liberação acentuada de substância ativa no cólon.
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0922233A2 (pt)	2018-05-29	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BR112012018374A2 (pt)	2017-03-28	derivados de ácido carboxílico de pirrolidina ou tiazolidina, composição farmacêutica e métodos para uso no tratamento de distúrbios metabólicos como agonistas de receptor 43 acoplado à proteína g (gpr43).
CL2008000021A1 (es)	2009-03-27	Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
BRPI1008727A2 (pt)	2016-03-08	derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos
BRPI0807285A2 (pt)	2014-05-06	"composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"